Search Results for "Lumpectomy Triple Negative Breast Cancer"
Matching Channels
Breast cancer in the UK is diagnosed in nearly 46,000 people each year, with just over 12,000 dying from breast cancer each year in he UK. There are several risk factors for developing b...
Epithelial cell adhesion molecule EpCAM CD326
Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian,...
Selective Estrogen Receptor Modulators SERMs
Selective estrogen receptor modulators (SERMs) act as estrogen receptor (ER) agonists or antagonist depending on the targeted tissue and the specific configuration of the used SERM. Effects on bone, e...
Matching News
In a study of more than 600 women with early-stage triple-negative breast cancer treated at a single institution, treatment with breast-conserving therapy was as effective as total mastectomy. These r...
Answering Your Questions About Triple-Negative Breast Cancer
Bhuvaneswari Ramaswamy MD, MRCP Assistant Professor of Internal Medicine Division of Medical Oncology Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University...
Combination of Afinitor and Chemotherapy Shows Promise in Metastatic, Triple-Negative Breast Cancer
According to results presented at the 2012 Breast Cancer Symposium, the combination of Afinitor® (everolimus; also known as RAD001) and carboplatin may provide a benefit in metastatic, triple-negativ...
Breast cancer survivors share their reconstruction stories. Gina M. Maisano, 50 Locust Valley, New York Founder, No Surrender Breast Cancer Foundation Author, Intimacy after Breast Cancer: Dealing Wit...
Aveo's Future Depends on Triple-Negative Breast Cancer
The story corrected to more accurately describe clinical trials involving Genentech's Avastin in triple-negative breast cancer patients. CAMBRIDGE, Mass. (TheStreet) -- Aveo Oncology will succeed or...
FDA Seeks to Speed Drug Development for Early-Stage, Triple-Negative Breast Cancer
In order to speed the availability of promising drugs for high-risk, early-stage breast cancer, the US Food and Drug Administration (FDA) has drafted new guidelines for clinical trials. These guidelin...
Drug shows promise for triple-negative breast cancer
(Medical Xpress) -- A promising new therapy for hard-to-treat triple-negative breast cancer has been reported in the journal Breast Cancer Research by a team at the Tulane University School of Medicin...
Anti-Copper Drug Might Prevent Organ Metastasis in Triple-Negative Breast Cancer
An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture migrating cancer tumor cells has shown surprising benefit in one o...
Matching PubMed Articles
To assess the potential mechanisms that may underlie increased local failure in triple negative (TN) breast cancers, an analysis was performed of the risk of residual carcinoma after lumpectomy with c...
Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.
Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers of mutations in BRCA1. However, few studies have assessed the associat...
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of population studies that determine the frequ...
Background Triple-negative (ie, estrogen receptor [ER], progesterone receptor, and HER2 negative) breast cancer occurs disproportionately among African American women compared with white women and is...
Triple-negative breast cancer.
Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuse...
